Phase I trial of anti HER2 antibody toxin conjugate [Zemab] for the treatment of HER2 positive head & neck cancer and breast cancer
Phase of Trial: Phase I
Latest Information Update: 24 Jun 2008
At a glance
- Drugs Anti-HER2 antibody-toxin conjugate (Primary)
- Indications Breast cancer; Head and neck cancer
- Focus Adverse reactions
- Sponsors TopoTarget
- 24 Jun 2008 New trial record.
- 14 May 2008 This study has been completed.